5Chong JY.Mohr JP.Anticoagulation and platelet antiaggregation therapy in stroke prevention.Current Opinion in Neurology,2005,18 (1):53-57.
6Levine SR,Brey RL,Tilley BC,et al.APASS Investigators.Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.J Am Med Assoc,2004,291 (5):576-584.
7Ruiz-Irastorza G,Egurbide MV,Ugalde J,et al.High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematousus.Arch Intern Med,2004,164 (1):77-82.
8Brey RL,Chapman J,Levine SR,et al.Stroke and the antipholipid syndrome:consensus meeting Taormina 2002.Lupus,2003,12(7):508-513.
9Sairam S,Baethge BA,McNearney T.Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies.Clin Rheumatol,2003,22(1):24-29.
4Levine JS, Branch DW, Rauch J. The antiphospholipid syn- drome[J]. N Engl J Med,2002,346(10) :752.
5Wilson WA, Gharavi AE, Koike T, et al. International con-sensus statement on preliminary classification criteria for definite an - tiphospholipid syndrome: report of an internationalworkshop [ J ]. Ar~hrifisRheum, 1999,42 (7) : 1309.
6Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome [ J ] . ArthritisPdleum, 2004,50(4) : 1028.
7Asherson RA, Cervera R, de Groot PG, eta. I Catastrophic an - tiphospholipid syndrome : international consensus statement on classification criteria and treatment guidelines[ J ] Lupus ,2003,12 (7) :530.
